scholarly journals High-Speed Burring with and without the Use of Surgical Adjuvants in the Intralesional Management of Giant Cell Tumor of Bone: A Systematic Review and Meta-Analysis

Sarcoma ◽  
2010 ◽  
Vol 2010 ◽  
pp. 1-5 ◽  
Author(s):  
H. Algawahmed ◽  
Robert Turcotte ◽  
F. Farrokhyar ◽  
M. Ghert
Keyword(s):  
Giant Cell Tumor ◽  
Giant Cell ◽  
Local Control ◽  
Fixed Effects ◽  
High Speed ◽  
Meta Analysis ◽  
Cell Tumor ◽  
Fixed Effects Model ◽  
Intralesional Curettage ◽  
Pooled Data

Local control rates for Giant Cell Tumor of Bone (GCT) have been reported in a large number of retrospective series. However, there remains a lack of consensus with respect to the need for a surgical adjuvant when intralesional curettage is performed. We have systematically reviewed the literature and identified six studies in which two groups from the same patient cohort were treated with intralesional curettage and high-speed burring with or without a chemical or thermal adjuvant. Studies were evaluated for quality and pooled data was analyzed using the fixed effects model. Data from 387 patients did not indicate improved local control with the use of surgical adjuvants. Given the available data, we conclude that surgical adjuvants are not required when meticulous tumor removal is performed.

scholarly journals A Systematic Review and Meta-Analysis of En-Bloc vs Intralesional Resection for Giant Cell Tumor of Bone of the Distal Radius

2013 ◽  
Vol 7 (1) ◽  
pp. 103-108 ◽  
Author(s):  
Theresa J.C Pazionis ◽  
Hussain Alradwan ◽  
Benjamin M Deheshi ◽  
Robert Turcotte ◽  
Forough Farrokhyar ◽  
...  
Keyword(s):  
Giant Cell Tumor ◽  
Giant Cell ◽  
Distal Radius ◽  
Wrist Joint ◽  
Meta Analysis ◽  
En Bloc Resection ◽  
Cell Tumor ◽  
En Bloc ◽  
Intralesional Curettage ◽  
Functional Benefit

Introduction: Surgical management of Giant Cell Tumor of Bone of the distal radius (GCTDR) remains controversial due to risk of local recurrence (LR) offset by functional limitations which result from en-bloc resection. This study aims to determine the oncologic and functional outcomes of wide excision (WE) vs intralesional curettage (IC) of GCTDR. Methods: A complete search of the applicable literature was done. Included studies reported on patients from the same cohort who were surgically treated for GCTDR with WE or IC. Two reviewers independently assessed all papers. The primary outcome measure was LR. Results: One-hundred-forty-one patients from six studies were included: 60 treated with WE, and 81 with IC. Five WE patients (8%) suffered LR whereas 25 IC patients (31%) did. The odds of LR were three times less in the WE group vs the IC group. MSTS1993 scores, where available, were on average 'good' with WE and 'excellent' with IC. Conclusions: Within statistical limitations the data support an attempt, where feasible, at wrist joint preservation and superior function with IC. Intralesional curettage is reasonable when the functional benefit outweighs the risk of recurrence as is the case in many cases of GCT of the distal radius.

scholarly journals Giant Cell Tumor of the Capitate Bone

2018 ◽  
Vol 10 (03) ◽  
pp. 158-161 ◽  
Author(s):  
Ahmadreza Afshar ◽  
Ali Tabrizi ◽  
Ali Aidenlou ◽  
Ata Abbasi
Keyword(s):  
Giant Cell Tumor ◽  
Giant Cell ◽  
High Speed ◽  
Cell Tumor ◽  
Intralesional Curettage ◽  
Allogenic Bone ◽  
High Speed Burr ◽  
The Right ◽  
Allogenic Bone Graft ◽  
Capitate Bone

AbstractThis case report describes a 16-year-old female patient with a giant cell tumor in her right capitate bone. The tumor was removed by intralesional curettage. A high-speed burr was used to extend the margins of the curettage, and alcohol irrigation was used for adjuvant therapy. The cavity of the capitate was filled with allogenic bone graft. There was no recurrence after 2 years of follow-up, and the right wrist radiographs demonstrated healing of the lesion.

scholarly journals Effect of bisphosphonates on local recurrence of giant cell tumor of bone: a meta-analysis

2019 ◽  
Vol Volume 11 ◽  
pp. 669-680 ◽  
Author(s):  
Mingmin Shi ◽  
Lei Chen ◽  
Yangxin Wang ◽  
Wei Wang ◽  
Yujie Zhang ◽  
...  
Keyword(s):  
Local Recurrence ◽  
Giant Cell Tumor ◽  
Giant Cell ◽  
Meta Analysis ◽  
Cell Tumor

Invasive Giant Cell Tumor of the Lateral Skull Base: A Systematic Review, Meta-Analysis, and Case Illustration

2016 ◽  
Vol 96 ◽  
pp. 47-57 ◽  
Author(s):  
Jacob L. Freeman ◽  
Soliman Oushy ◽  
Jeffrey Schowinsky ◽  
Stefan Sillau ◽  
A. Samy Youssef
Keyword(s):  
Systematic Review ◽  
Skull Base ◽  
Giant Cell Tumor ◽  
Giant Cell ◽  
Meta Analysis ◽  
Cell Tumor ◽  
Case Illustration ◽  
Lateral Skull Base

scholarly journals Giant Cell Tumor: A Rare Condition in the Immature Skeleton—A Retrospective Study of Symptoms, Treatment, and Outcome in 16 Children

Sarcoma ◽  
2016 ◽  
Vol 2016 ◽  
pp. 1-6 ◽  
Author(s):  
Thale M. Asp Strøm ◽  
Anette Torød Skeie ◽  
Ingvild Koren Lobmaier ◽  
Olga Zaikova
Keyword(s):  
Retrospective Study ◽  
Giant Cell Tumor ◽  
Giant Cell ◽  
Rare Condition ◽  
Functional Results ◽  
Cell Tumor ◽  
Initial Symptom ◽  
Recurrence Rates ◽  
Intralesional Curettage ◽  
Immature Skeleton

Background. Pediatric giant cell tumor (GCT) of bone is rare and the course of the disease in the immature skeleton is sparsely described. We performed a retrospective study addressing symptoms, treatment, and outcome in children with GCT.Methods. Review of medical records and images of patients with GCT. Patients were detected from our hospital prospective database and those with open epiphyseal cartilages were included.Results. 16 children (75% girls) from 6 to 15 years old were identified. Eight lesions (50%) were in long bones and 4 (25%) in flat bones. One lesion appeared to be purely epiphyseal. All patients had pain as the initial symptom. Local recurrence developed in 2 patients. 14 of 16 patients returned to normal activity with no sequelae. One patient developed anisomelia after surgery.Conclusions. The biological tumor behavior in children does not seem to differ from what is reported in adults. Lesions in flat bones are very unusual, but our data alone do not provide enough evidence to conclude that this is more common in the immature skeleton. Literature review showed only one previous case report describing a purely epiphyseal GCT. Intralesional curettage is appropriate treatment and gives good functional results with acceptable recurrence rates.

scholarly journals Pre-operative denosumab is associated with higher risk of local recurrence in giant cell tumor of bone: a systematic review and meta-analysis

2020 ◽  
Author(s):  
Xi Chen ◽  
Hairui Li ◽  
Shibai Zhu ◽  
Yiou Wang ◽  
Wenwei Qian
Keyword(s):  
Local Recurrence ◽  
Giant Cell Tumor ◽  
Giant Cell ◽  
Meta Analysis ◽  
Cell Tumor ◽  
Cochrane Library ◽  
Control Group ◽  
Risk Of Recurrence ◽  
Increased Risk ◽  
The Cochrane Library

Abstract Background: In 2013, denosumab was introduced as peri-operative adjuvant treatment for giant cell tumor (GCT) of bone as it inhibits osteoclast activity. It is suggested that denosumab relives pain, facilitate curettage in lesions requiring resection initially. However, controversy remains whether denosumab increases the risk of local recurrence after surgery. Methods: Medline, Embase and the Cochrane Library were comprehensively searched in June 2019 to identify studies investigating the clinical outcome of GCT of bone with and without peri-operative denosumab after surgery. Data were gathered and a meta-analysis was conducted. Result: Ten studies with 1082 cases (169 in denosumab group, 913 in control group) were included. Overall, denosumab was associated with significantly higher risk of recurrence(P<0.02) and inferior 5 year recurrence free survival(P=0.000). Denosumab and curettage has a relatively higher risk of recurrence comparing to curettage alone(P=0.07). The risk of recurrence is not significantly increased if denosumab was administered both preoperatively and postoperatively(P=0.24). Conclusion: Administration of denosumab is associated with increased risk of recurrence due to a variety of reasons, though it is proven effective in relieving pain, enabling curettage and improved functional outcome. Post-operative denosumab is recommended as it continuously suppress/eliminate residue tumor cells.

Sign in / Sign up

Export Citation Format

Share Document